Inotek

Inotek Pharmaceuticals Corporation is a development-stage pharmaceutical company that previously entered patients into phase II trial for its compound IND-001, for the prevention of cardiac necrosis. INO-1001 is a potent inhibitor of PARP.

It is based in Beverly, Massachusetts.